EUCTR2007-002337-36-GB进行中（未招募）1 期
An open-labelled study of the cerebrospinal fluid pharmacokinetics of intravenous Kineret® in patients with subarachnoid haemorrhage - IL-1RA in SAH PK STUDY 2
Salford Royal NHS Foundation Trust0 个研究点目标入组 100 人开始时间: 2007年7月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Inclusion criteria for study enrollment.
- •Patients with confirmed spontaneous SAH who are thought likely to, or are known to require,the placement of an EVD as part of their clinical care. Also, patients who have already had an EVD placed will be eligible.
- •No concomitant health problems that, in the opinion of the Principal Investigator or Chief Investigator or designee, would interfere with participation, administration of study treatment or assessment of outcomes including safety, for example, pre-existing malignancy.
- •No confirmed or suspected serious infection at the time of study entry.
- •Renal function within normal limits (serum creatinine< 177 µmol/l).
- •Willing and able to give informed consent or consent available from a patient representative (usually next of kin) for study inclusion including agreement in principle to receive study intervention and undergo all study assessments.
- •Aged 16 years or above.
- •Eligibility Criteria for Study Entry (to receive study intervention).
- •In addition to meeting the requirements specified above, patients who are entered fully into the study will also meet the following criteria:
- •EVD in place that is expected to remain in situ for the next 24-48 hours.
- •Likely to remain resident within the centre for the next seven days.
- •Willing to consent to inclusion in the study or consent available from the patient’s representative on the patient’s behalf.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion Criteria for Study Enrolment
- •Unconfirmed or uncertain diagnosis of spontaneous SAH.
- •Known or suspected infection at the time of consideration for the study.
- •Impaired renal function defined as serum Creatinine > 177 µmol/l.
- •Known allergy to E. coli or any of the constituents of the study medication as established from the patient themselves, reliable representative and clinical records.
- •Previous or concurrent treatment with anakinra or Kineret®, known at the time of study entry.
- •Previous or current treatment with medication suspected of interacting with Kineret®, such as TNF-a inhibitors.
- •Evidence of serious infection.
- •Known to have participated in a clinical trial of an investigational agent or device in the previous 30 days or for the period determined by the protocol of the study the patient has taken part in.
- •Known pregnancy or breast-feeding.
- •Clinically significant concurrent medical condition, at the Chief Investigator’s (or designee’s) discretion, which could affect the safety, tolerability, or efficacy in this study.
- •Previous inclusion in the current study (known prior to inclusion).
- •Inability or unwillingness of patient or patient’s personal representative to give informed consent.
- •Aged below 16.
- •Exclusion from full study entry (to receive study intervention).
- •EVD not placed.
- •EVD is expected to be removed within 24 h.
- •Likely to be transferred from the centre within the next seven days.
- •Unwilling to consent to inclusion in the study or consent unavailable from the patient’s representative on the patient’s behalf.
研究者
相似试验
已完成
不适用
An investigation on spinal fluid in patients with sciatica-type or nerve-type pain of the lower limbeuropathic lower limb painNervous System DiseasesISRCTN34007592Trinity Translational Medicine Institute12
已完成
不适用
A study to examine cerebrospinal fluid transitivity and efficacy of afatinib in carcinomatous meningitis patients with non-small cell lung cancer patients harboring EGFR mutation.carcinomatous meningitis patients with NSCLC harboring EGFR mutationJPRN-UMIN000014065Kinki-Chuo Chest Medical Center10
已完成
不适用
The study analyzing blood and cerebrospinal fluids from the patients with early onset Alzheimer disease to discover causative factors and biomarkersDiseases of the nervous systemKCT0000847Soon Chun Hyang University Hospital Bucheon516
已完成
不适用
Plasma and cerebrospinal fluid concentrations treated with daily dose and high dose weekly erlotinib in non-small cell lung cancer patients with central nervous system metastasescentral nervous system metastases of non-small cell lung cancer with active EGFR mutations treated with daily dosing erlotinibJPRN-UMIN000004703Osaka City University10
招募中
不适用
Assessment of Cerebrospinal Fluid Flow Related Disorders Using a Phase-contrast Magnetic Resonance Imaging Technique.Cerebrospinal FluidNCT03656016Assiut University87